Abstract Number: 1276 • ACR Convergence 2023
Multimorbidity Burden Predicts Lower Likelihood of Remission in Patients with Rheumatoid Arthritis
Background/Purpose: Seropositivity has historically been associated with poor disease outcomes in patients with rheumatoid arthritis (RA). Seronegative RA is on the rise and is associated…Abstract Number: 1408 • ACR Convergence 2023
Impact of Disease Activity on Functional Impairment in Patients with Spondyloarthritis Is Different According to the Degree of Radiographic Progression: Result from SNUH-AS Cohort
Background/Purpose: Although previous studies suggested that physical functioning is largely driven by disease activity in patients with spondyloarthritis (SpA), its relationship to radiographic progression has…Abstract Number: 1672 • ACR Convergence 2023
Association of COVID-19 Vaccinations with Flares of Systemic Rheumatic Disease: A Case-Crossover Study
Background/Purpose: Fear of flare contributes to COVID-19 vaccine hesitancy in patients with systemic rheumatic diseases (SRD). Accurately ascertaining post-vaccine SRD flares and differentiating them from…Abstract Number: 2187 • ACR Convergence 2023
Association Between Illness Perception, Anxiety and Depression State, Disease Activity and Glucocorticoid Therapy in Patients with Sjӧgren’s Syndrome
Background/Purpose: Sjӧgren's syndrome (SS) may affect several aspects of patients' daily lives, leading to impairment of quality of life and patient functioning. Aims of this…Abstract Number: 2317 • ACR Convergence 2023
Effect of SLE-DAS Remission on Quality of Life in Patients with Systemic Lupus Erythematosus: A Cross-sectional Validation Study
Background/Purpose: The SLE Disease Activity Score (SLE-DAS) has been developed and validated in Italian patients with SLE. The objective of this study was to evaluate…Abstract Number: 2559 • ACR Convergence 2023
Clinical Manifestations and Immunomodulatory Treatment in Patients with Relapsing Polychondritis
Background/Purpose: Relapsing polychondritis (RP) is a rare systemic inflammatory disease without standard treatment guidelines. This study aims to investigate the clinical characteristics, current treatment approaches,…Abstract Number: 0220 • ACR Convergence 2023
Paxlovid (Nirmatrelvir Plus Ritonavir) in Patients with Underlying Rheumatological Diseases, in Preventing COVID-19 Related Hospitalization and Death
Background/Purpose: The benefits of antiviral therapy in the COVID-19 patients with underlying rheumatic disease with or without immunosuppression are not entirely clear. The goal of…Abstract Number: 0445 • ACR Convergence 2023
Comparison of the Efficacy, Safety and Immunogenicity of a Proposed Biosimilar MSB11456 with Tocilizumab Reference Product in Moderate-to-severe Rheumatoid Arthritis: Results of a Randomized Double-blind Study
Background/Purpose: Tocilizumab is an anti‑interleukin‑6 receptor monoclonal antibody indicated for treating rheumatoid arthritis (RA) and other inflammatory diseases. MSB11456 is a proposed biosimilar to US‑licensed…Abstract Number: 0587 • ACR Convergence 2023
Impact of up to 24 Months Intravenous (IV) Belimumab (BEL) Treatment on Steroid Use and Disease Activity in Patients with SLE in Clinical Practice: Additional Post Hoc Pooled Analysis of Multicountry OBSErve Cohort Data
Background/Purpose: The clinical effectiveness of 6-month IV BEL use in SLE has previously been described in a post hoc pooled analysis from six OBSErve cohort…Abstract Number: 0978 • ACR Convergence 2023
Identifying Important Clinical Features for Predicting Remission in Patients with Rheumatoid Arthritis Treated with Biologics Using Machine Learning Model
Background/Purpose: Biologic disease-modifying antirheumatic drugs (bDMARDs) offer promising results for rheumatoid arthritis (RA) patients in general, but a substantial percentage of patients do not respond…Abstract Number: 1292 • ACR Convergence 2023
Active Rheumatoid Arthritis Patients Exhibit an Altered Serum Lipidomic Profile Directly Linked to Disease Activity, Which Is Reversed by Biologic and Targeted Synthetic DMARD
Background/Purpose: Lipid metabolism impacts immune cell plasticity, activation, differentiation, and function, making the analysis of the lipidomic profile crucial in understanding chronic inflammatory diseases like…Abstract Number: 1412 • ACR Convergence 2023
Improvements in Patient-Reported Outcomes Through 6 Months of Guselkumab Treatment in Patients with Active Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Background/Purpose: Guselkumab (GUS) has demonstrated significant efficacy across disease domains in controlled clinical trials of patients (pts) with active PsA.1,2 Recent CorEvitas PsA/SpA Registry analyses…Abstract Number: 1685 • ACR Convergence 2023
SLE Disease Activity Is a More Important Risk Factor Than Immunosuppression for Acquiring Human Papillomavirus (HPV) Infection in Systemic Lupus Erythematosus Patients
Background/Purpose: SLE patients have increased rates of HPV infection and cervical cancer. Although some factors are recognized for HPV infection in SLE, the relationship with…Abstract Number: 2198 • ACR Convergence 2023
Which Factors Are Associated with Clinically High Disease Activity in Axial Spondyloarthritis? Results from the International Map of Axial Spondyloarthritis (IMAS)
Background/Purpose: Active axial spondyloarthritis (axSpA) is associated with poorer physical and mental health outcomes. This study aims to assess the prevalence of clinically active disease…Abstract Number: 2321 • ACR Convergence 2023
Does the Perspective of SLE Patients Match the Expert Opinion and Definitions of Remission and Low Disease Activity State? Prospective Analysis of 500 Patients from a Spanish Multicenter Cohort
Background/Purpose: There is no information available regarding whether the patient's perception of disease activity aligns with current definitions of DORIS 2021 remission and Lupus Low…
- « Previous Page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- …
- 112
- Next Page »